Group items matching

in title, tags, annotations or url

Vieth R, Chan PC, MacFarlane GD.Efficacy and safety of vitamin D3 intake exceeding the lowest observedadverse effect level.Am J Clin Nutr. 2001 Feb;73(2):288-94.PMID: 11157326 [PubMed - indexed for MEDLINE]

Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.Am J Clin Nutr. 2003 Jan;77(1):204-10. Erratum in: Am J Clin Nut

Valimaki VV, Loyttyniemi E, Valimaki MJ.\nVitamin D fortification of milk products does not resolve\nhypovitaminosis D in young Finnish men.\nEur J Clin Nutr. 2006 Nov 29; [Epub ahead of print]\nPMID: 17136043 [PubMed - as supplied by publisher]

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. Review. PMID: 16825677

Vieth R.Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.Am J Clin Nutr. 1999 May;69(5):842-56. Review.PMID: 10232622 [PubMed - indexed for MEDLINE]

Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A. \nThe urgent need to recommend an intake of vitamin D that is

Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Am J Clin Nutr. 2009 May 13. [Epub ahead of print] PMID: 19439458 doi:10.3945/ajcn.2008.27326

Conclusion: The associations suggest that replacing SFAs with PUFAs rather than MUFAs or carbohydrates prevents CHD over a wide range of intakes. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Bälter K, Fraser GE, Goldbourt U, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A. Am J Clin Nutr. 2009 May;89(5):1425-32. Epub 2009 Feb 11. PMID: 19211817 doi:10.3945/ajcn.2008.27124

The Vitamin D Pandemic and its Health Consequences\nPresented by Michael Holick, PhD, MD, Professor of medicine, physiology and biophysics and director of the General Clinical Research Center at Boston University Medical Center\nKeynote address at the opening ceremony of the 34th European Symposium on Calcified Tissues, Copenhagen 5 May, 2007\n

Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Kidd P. Altern Med Rev. 2003 Aug;8(3):223-46. Review. PMID: 12946237 Th1 pathways typically produce activation of cytotoxic T lymphocytes (Tc), NK cells, macrophages, and monocytes, all of which can attack cancer cells and generally defend against tumors. 55 IFN-gamma and other Th1 cytokines are typically lower in advanced cancer patients, while the Th2 marker IL-4 can be higher or unchanged.56 Nodules of non-small cell lung cancer freshly removed from patients expressed a marked imbalance toward Th2, as did biopsy samples from basal cell carcinoma.57 In prostate cancer patients IL-2 was low (Th1) and IL-10 high.58 IL-10 is a confirmed Th1-suppressive cytokine, and heightened IL-10 is a common factor in cancer.55 IL-10 has a variety of suppressive effects that include inhibiting Th1 cytokine production, down-regulating APC and NK cell function, and lowering overall T-cell proliferation.57 Especially under the influence of IL-4 (Th2), tumor cells apparently up-regulate IL-10 that suppresses nearby killer cells. Tumor-derived IL-10 has been documented in lymphoma, ovarian carcinoma, melanoma, neuroblastoma, and renal cell and colon carcinoma.57 IL-12 is another cytokine that can be up-regulated by Th1 activity and inhibited by Th2.59 A low IL-12/IL-10 ratio was found in cervical cancer patients.55 Recent clinical studies suggest elevated IL-10 is predictive of a poor prognosis. 57 With both IL-4 and IL-10 being proven inhibitors of Th1 and promoters of Th2 activity, the recognized capability of cancerous tissue to suppress immunity is readily rationalized.

new (March 24th) report in Clinical Cancer Research, a journal of the American Association for Cancer Research, shows that Omega-3 fatty acids appear protective against advanced prostate cancer. Dr. John S. Witte, Ph.D., professor of epidemiology and biostatistics at the University of California San Francisco, says that previous research has shown protection against prostate cancer, but that this is one of the first studies to show protection against advanced prostate cancer.

Floyd Chilton and colleagues wanted to examine whether theses fatty acids might have other effects, and developed a dietary intervention strategy in which 27 healthy humans were fed a controlled diet mimicking the w6/w3 ratios of early humans over 5 weeks. They then looked at the gene levels of immune signals and cytokines (protein immune messengers), that impact autoimmunity and allergy in blood cells and found that many key signaling genes that promote inflammation were markedly reduced compared to a normal diet, including a signaling gene for a protein called PI3K, a critical early step in autoimmune and allergic inflammation responses. This study demonstrates, for the first time in humans, that large changes in gene expression are likely an important mechanism by which these omega fatty acids exert their potent clinical effects

Our findings suggest that administration of n-3 FA (EPA and DHA) in doses of at least 1.5 g/day for a prolonged period of time to patients with advanced cancer is associated with an improvement in clinical, biological and QoL parameters. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. Br J Nutr. 2007 May;97(5):823-31. Review. PMID: 17408522 doi:10.1017/S000711450765795X

Derived from the bulb or clove of the plant. Garlic is used as a spice and to treat hyperlipidemia, hypertension, atherosclerosis, cancer, and infections. Processing can have a substantial effect on the chemical content in garlic; the volatile oil components are sensitive to heat and certain enzymes are acid-labile. Several oral garlic formulations are available, and clinical studies have addressed a variety of the proposed claims. Placebo-controlled trials on the cholesterol lowering effect of garlic yielded mixed results (16) (17) (18) (21) (22) (26). Studies evaluating the antithrombotic effects repeatedly have shown modest reduction in platelet aggregation, but varying levels of fibrinolytic activity. Research shows mixed effects with regard to reductions in blood glucose, blood pressure, or risk of cardiovascular disease (23). Frequently reported adverse events include bad breath, headache, fatigue, GI upset, diarrhea, sweating, and possible hypoglycemia (9). Because garlic is known to decrease platelet aggregation and potentially elevate the INR, it should not be used with anticoagulants or in patients with platelet dysfunction (15). Garlic appears to induce cytochrome p450 3A4 and may enhance metabolism of many medications (e.g. cyclosporin and saquinavir) (12). An analysis of several case-control studies in Europe suggests an inverse association between garlic consumption and risk of common cancers (25).

High prevalence of vitamin D inadequacy and implications for health.\nHolick MF.\nMayo Clin Proc. 2006 Mar;81(3):353-73. Review.\nPMID: 16529140 \ndoi: 10.4065/​81.3.353\n

Pittas AG, Lau J, Hu FB, Dawson-Hughes B. \nThe role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.\nJ Clin Endocrinol Metab. 2007 Jun;92(6):2017-29. Epub 2007 Mar 27. Review.\nPMID: 17389701 [PubMed - indexed for MEDL

Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, Knol DL, Lips P. \nVitamin D status predicts physical performance and its decline in older persons.\nJ Clin Endocrinol Metab. 2007 Jun;92(6):2058-65. Epub 2007 Mar 6.\nPMID: 17341569 [PubMed

Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. \nA higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study.\nJ Am Geriatr Soc. 2007 Feb;55(2):234-9.\nPMID: 17302660 [PubMed -

Valimaki VV, Alfthan H, Lehmuskallio E, Loyttyniemi E, Sahi T, Stenman UH, Suominen H, Valimaki MJ.\nVitamin D status as a determinant of peak bone mass in young Finnish men.\nJ Clin Endocrinol Metab. 2004 Jan;89(1):76-80.\nPMID: 14715830 [PubMed - indexe

What can we expect from omega-3 fatty acids? Chan EJ, Cho L. Cleve Clin J Med. 2009 Apr;76(4):245-51. PMID: 19339640 doi: 10.3949/ccjm.76a.08042